Next Generation TAVR Technology Now Available at Englewood Health

Englewood Hospital is One of First Hospitals in the Country to Use Evolut™ FX+ System

October 3, 2024 – Englewood Health has upgraded its capabilities for treating severe aortic valve stenosis with the addition of the Evolut™ FX+ Transcatheter Aortic Valve Replacement (TAVR) system, the newest generation of Medtronic’s TAVR platform. Interventional cardiologists and cardiothoracic surgeons at Englewood Hospital recently performed their first procedure, making Englewood’s award-winning heart team among the first heart centers in the country to use this upgraded system since it became commercially available after being FDA approved earlier this year.

“This investment in upgraded technology enables our specialists to more effectively treat patients with severe aortic valve stenosis, providing greater options for patients with advanced disease,” says Joseph De Gregorio, MD, executive director of cardiovascular services at Englewood Hospital.

This latest iteration of the Evolut TAVR system offers larger coronary access windows through a modified frame design, which is four times larger than the previous system. The system provides increased space for catheter maneuverability to facilitate access through the coronary arteries of varying patient anatomies.

“The enhanced accessibility of this technology allows us to treat even more patients with severe aortic valve stenosis, reduces symptoms, and improves outcomes,” says Ramin Hastings, MD, medical director of the Structural Heart and Valve Program at Englewood Hospital.

Severe aortic stenosis is a condition where the aortic valve leaflets no longer open and close properly due to stiffness of the leaflets, causing the heart to work harder to pump blood to the rest of the body. Over time, aortic valve stenosis can cause a variety of symptoms, reducing a patient’s quality of life, and can lead to heart failure.

The Evolut FX+ TAVR system can be used to treat symptomatic severe aortic stenosis patients across all risk categories.